Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 9 | 2023 | 173 | 4.350 |
Why?
|
| Hospitalization | 12 | 2023 | 281 | 3.260 |
Why?
|
| Arthritis, Rheumatoid | 7 | 2022 | 249 | 2.200 |
Why?
|
| Psoriasis | 3 | 2021 | 5 | 2.120 |
Why?
|
| Scleroderma, Systemic | 3 | 2022 | 7 | 1.700 |
Why?
|
| Myositis | 7 | 2022 | 16 | 1.660 |
Why?
|
| Granulomatosis with Polyangiitis | 3 | 2022 | 9 | 1.600 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2023 | 8 | 1.540 |
Why?
|
| Inpatients | 9 | 2022 | 114 | 1.530 |
Why?
|
| Acute Coronary Syndrome | 2 | 2022 | 10 | 1.480 |
Why?
|
| Patient Readmission | 3 | 2023 | 117 | 1.390 |
Why?
|
| Brain Ischemia | 2 | 2022 | 61 | 1.340 |
Why?
|
| Adult | 26 | 2023 | 6826 | 1.260 |
Why?
|
| Humans | 46 | 2023 | 22592 | 1.180 |
Why?
|
| Dermatomyositis | 4 | 2023 | 9 | 1.080 |
Why?
|
| Hospital Mortality | 6 | 2023 | 126 | 1.040 |
Why?
|
| Polymyositis | 4 | 2023 | 7 | 1.010 |
Why?
|
| Creatine Kinase | 6 | 2015 | 19 | 0.850 |
Why?
|
| Retrospective Studies | 17 | 2023 | 2954 | 0.840 |
Why?
|
| Rheumatic Diseases | 3 | 2021 | 52 | 0.830 |
Why?
|
| United States | 9 | 2022 | 1741 | 0.810 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2022 | 2 | 0.790 |
Why?
|
| Sarcoidosis | 1 | 2022 | 12 | 0.770 |
Why?
|
| Lung Diseases | 1 | 2022 | 36 | 0.760 |
Why?
|
| Immunoglobulin G | 6 | 2013 | 67 | 0.760 |
Why?
|
| Antirheumatic Agents | 6 | 2013 | 84 | 0.760 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2022 | 4 | 0.750 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 9 | 0.750 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2022 | 4 | 0.750 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 5 | 0.750 |
Why?
|
| Gout | 1 | 2022 | 5 | 0.750 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2022 | 2 | 0.740 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 9 | 0.730 |
Why?
|
| Microscopic Polyangiitis | 1 | 2021 | 2 | 0.720 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2021 | 2 | 0.720 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 27 | 0.720 |
Why?
|
| Cerebrovascular Disorders | 1 | 2022 | 95 | 0.680 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 97 | 0.650 |
Why?
|
| Stroke | 1 | 2022 | 236 | 0.600 |
Why?
|
| Rheumatology | 2 | 2022 | 77 | 0.590 |
Why?
|
| Aspartate Aminotransferases | 2 | 2015 | 13 | 0.580 |
Why?
|
| Alanine Transaminase | 2 | 2015 | 15 | 0.580 |
Why?
|
| Risk Factors | 6 | 2023 | 1955 | 0.580 |
Why?
|
| Tuberculosis | 5 | 2013 | 18 | 0.580 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2008 | 165 | 0.490 |
Why?
|
| Paracentesis | 1 | 2015 | 4 | 0.460 |
Why?
|
| Female | 20 | 2023 | 12734 | 0.450 |
Why?
|
| Arthritis, Psoriatic | 3 | 2017 | 14 | 0.450 |
Why?
|
| Fluoroscopy | 1 | 2015 | 32 | 0.450 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2005 | 9 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 163 | 0.430 |
Why?
|
| Spondylitis, Ankylosing | 3 | 2010 | 20 | 0.420 |
Why?
|
| Arthritis, Infectious | 3 | 2017 | 47 | 0.420 |
Why?
|
| Uveoparotid Fever | 1 | 2013 | 1 | 0.410 |
Why?
|
| Parotid Gland | 1 | 2013 | 14 | 0.410 |
Why?
|
| Etanercept | 7 | 2017 | 21 | 0.380 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2022 | 39 | 0.350 |
Why?
|
| Immunosuppressive Agents | 5 | 2017 | 113 | 0.340 |
Why?
|
| Incidence | 3 | 2022 | 618 | 0.340 |
Why?
|
| Hospitals | 2 | 2022 | 155 | 0.340 |
Why?
|
| Databases, Factual | 2 | 2022 | 300 | 0.330 |
Why?
|
| Length of Stay | 2 | 2021 | 293 | 0.310 |
Why?
|
| Middle Aged | 13 | 2023 | 7800 | 0.310 |
Why?
|
| Immunoconjugates | 1 | 2008 | 7 | 0.280 |
Why?
|
| Male | 12 | 2023 | 12260 | 0.280 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 302 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor | 6 | 2013 | 26 | 0.240 |
Why?
|
| Arthritis, Juvenile | 2 | 2009 | 7 | 0.230 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2009 | 17 | 0.220 |
Why?
|
| Aged | 7 | 2022 | 7300 | 0.210 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 1 | 0.210 |
Why?
|
| Sjogren's Syndrome | 1 | 2023 | 3 | 0.210 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 26 | 0.210 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2003 | 2 | 0.210 |
Why?
|
| Peritonitis | 1 | 2003 | 17 | 0.200 |
Why?
|
| Pulmonary Alveoli | 1 | 2022 | 20 | 0.200 |
Why?
|
| Venous Thrombosis | 1 | 2023 | 40 | 0.190 |
Why?
|
| Sepsis | 1 | 2023 | 77 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2022 | 72 | 0.190 |
Why?
|
| Hemiplegia | 1 | 2022 | 3 | 0.190 |
Why?
|
| Vasoconstriction | 1 | 2022 | 14 | 0.190 |
Why?
|
| Kidney | 1 | 2003 | 139 | 0.190 |
Why?
|
| Paresis | 1 | 2022 | 16 | 0.190 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 10 | 0.180 |
Why?
|
| Autoantibodies | 1 | 2022 | 60 | 0.180 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2021 | 8 | 0.180 |
Why?
|
| Young Adult | 4 | 2022 | 1607 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 68 | 0.180 |
Why?
|
| Hospital Charges | 1 | 2021 | 14 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2022 | 2915 | 0.170 |
Why?
|
| Adolescent | 3 | 2022 | 1855 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 83 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2022 | 198 | 0.150 |
Why?
|
| Prednisone | 2 | 2015 | 64 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1038 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 99 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 42 | 0.130 |
Why?
|
| Methylprednisolone | 1 | 2015 | 15 | 0.120 |
Why?
|
| Metatarsophalangeal Joint | 1 | 2015 | 5 | 0.110 |
Why?
|
| Injections, Intra-Articular | 1 | 2015 | 56 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 95 | 0.110 |
Why?
|
| Wrist Joint | 1 | 2015 | 56 | 0.110 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2014 | 3 | 0.110 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2014 | 3 | 0.110 |
Why?
|
| Infliximab | 3 | 2013 | 17 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 314 | 0.100 |
Why?
|
| Head | 1 | 2013 | 16 | 0.100 |
Why?
|
| Tuberculin Test | 3 | 2009 | 9 | 0.100 |
Why?
|
| Antitubercular Agents | 3 | 2013 | 12 | 0.100 |
Why?
|
| Adalimumab | 2 | 2013 | 16 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 1403 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 574 | 0.080 |
Why?
|
| Troponin T | 1 | 2009 | 3 | 0.080 |
Why?
|
| Troponin I | 1 | 2009 | 11 | 0.080 |
Why?
|
| Isoniazid | 1 | 2009 | 3 | 0.080 |
Why?
|
| Transaminases | 1 | 2009 | 6 | 0.080 |
Why?
|
| Methotrexate | 1 | 2009 | 36 | 0.080 |
Why?
|
| Myocardium | 1 | 2009 | 100 | 0.080 |
Why?
|
| Vasculitis | 1 | 2009 | 26 | 0.080 |
Why?
|
| Liver | 1 | 2009 | 136 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 789 | 0.070 |
Why?
|
| Abatacept | 1 | 2008 | 6 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 26 | 0.070 |
Why?
|
| Rituximab | 1 | 2008 | 38 | 0.070 |
Why?
|
| Hip Joint | 1 | 2010 | 246 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 50 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 93 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 28 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2009 | 537 | 0.060 |
Why?
|
| ADAMTS13 Protein | 1 | 2005 | 5 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 10 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 86 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 189 | 0.060 |
Why?
|
| Muscle Strength | 2 | 2015 | 99 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2005 | 37 | 0.060 |
Why?
|
| Therapeutic Irrigation | 1 | 2004 | 44 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 69 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 62 | 0.050 |
Why?
|
| Paraplegia | 1 | 2023 | 5 | 0.050 |
Why?
|
| Seizures | 1 | 2023 | 62 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 242 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 41 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 151 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 101 | 0.050 |
Why?
|
| Biopsy | 1 | 2003 | 188 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 333 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2022 | 28 | 0.050 |
Why?
|
| Teaching | 1 | 2022 | 46 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2021 | 18 | 0.050 |
Why?
|
| Physical Examination | 1 | 2022 | 85 | 0.050 |
Why?
|
| Echocardiography | 1 | 2021 | 60 | 0.040 |
Why?
|
| Biomarkers | 2 | 2014 | 455 | 0.040 |
Why?
|
| Obesity | 1 | 2023 | 288 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 477 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2022 | 190 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2017 | 21 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 68 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 81 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2015 | 7 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2015 | 3 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 47 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 161 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 244 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 44 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2014 | 32 | 0.030 |
Why?
|
| Quebec | 1 | 2013 | 2 | 0.020 |
Why?
|
| Latent Tuberculosis | 1 | 2013 | 2 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 3657 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 48 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 578 | 0.020 |
Why?
|
| Mass Screening | 1 | 2013 | 152 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 1247 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 161 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 44 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 1386 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2004 | 4 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 158 | 0.010 |
Why?
|
| Child | 1 | 2004 | 1148 | 0.010 |
Why?
|